Research Analysts Set Expectations for GLSI Q1 Earnings

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Free Report) - Research analysts at HC Wainwright reduced their Q1 2025 EPS estimates for shares of Greenwich LifeSciences in a research note issued to investors on Monday, April 21st. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings per share of ($0.24) for the quarter, down from their prior estimate of ($0.21). HC Wainwright has a "Buy" rating and a $39.00 price objective on the stock. The consensus estimate for Greenwich LifeSciences' current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for Greenwich LifeSciences' Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.23) EPS, Q4 2025 earnings at ($0.23) EPS and FY2025 earnings at ($0.94) EPS.

Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) last announced its quarterly earnings data on Tuesday, April 15th. The company reported ($0.61) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.40).

Greenwich LifeSciences Price Performance

Shares of NASDAQ:GLSI opened at $9.63 on Wednesday. Greenwich LifeSciences has a 1 year low of $8.06 and a 1 year high of $18.75. The company has a market cap of $127.83 million, a P/E ratio of -12.04 and a beta of 1.76. The stock's fifty day moving average price is $10.77 and its 200-day moving average price is $12.31.

Insider Buying and Selling at Greenwich LifeSciences

In other news, CEO Snehal Patel purchased 3,600 shares of the stock in a transaction dated Monday, April 7th. The shares were purchased at an average cost of $9.10 per share, with a total value of $32,760.00. Following the acquisition, the chief executive officer now directly owns 5,561,602 shares of the company's stock, valued at $50,610,578.20. This represents a 0.06 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In the last 90 days, insiders have purchased 14,500 shares of company stock worth $129,267. Company insiders own 51.67% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Wells Fargo & Company MN grew its stake in shares of Greenwich LifeSciences by 54.8% during the 4th quarter. Wells Fargo & Company MN now owns 2,847 shares of the company's stock valued at $32,000 after purchasing an additional 1,008 shares during the period. Brown Brothers Harriman & Co. bought a new stake in Greenwich LifeSciences during the fourth quarter valued at approximately $45,000. JPMorgan Chase & Co. increased its holdings in Greenwich LifeSciences by 172.0% during the fourth quarter. JPMorgan Chase & Co. now owns 7,061 shares of the company's stock valued at $79,000 after buying an additional 4,465 shares during the last quarter. Bank of America Corp DE increased its holdings in Greenwich LifeSciences by 22.3% during the fourth quarter. Bank of America Corp DE now owns 7,262 shares of the company's stock valued at $82,000 after buying an additional 1,322 shares during the last quarter. Finally, Rhumbline Advisers raised its position in Greenwich LifeSciences by 48.7% in the first quarter. Rhumbline Advisers now owns 9,673 shares of the company's stock worth $92,000 after acquiring an additional 3,168 shares during the period. Institutional investors own 4.16% of the company's stock.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.